Drug
Isophosphamide mustard clinical trials
Also written ZIO-201 and palifosfamide-tris.
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2008 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Alaunos Therapeutics (10) · Indiana University School of Medicine (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses isophosphamide mustard is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue SarcomaTerminatedPhase 3Alaunos TherapeuticsNCT01168791Written as Palifosfamide-Tris
- Study of ZIO-201 in Advanced SarcomaCompletedPhase 1/2Alaunos TherapeuticsNCT00439686Written as ZIO-201
- A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue SarcomaTerminatedPhase 2Alaunos TherapeuticsNCT00718484Written as Palifosfamide-Tris
- Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)TerminatedPhase 3Alaunos TherapeuticsNCT01555710Written as Palifosfamide-tris
- Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With MalignanciesCompletedPhase 1Alaunos TherapeuticsNCT01242072Written as palifosfamide-tris
- Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid TumorsCompletedPhase 1Alaunos TherapeuticsNCT01340547Written as palifosfamide-tris
- Study of Oral Palifosfamide Tris in Solid TumorsWithdrawnPhase 1Alaunos TherapeuticsNCT00607711Written as oral palifosfamide tris
- Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.TerminatedPhase 2Alaunos TherapeuticsNCT01703754Written as Palifosfamide
- Palifosfamide in Treating Patients With Recurrent Germ Cell TumorsTerminatedPhase 2Indiana University School of MedicineNCT01808534Written as palifosfamide
- A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced CancerCompletedPhase 1Alaunos TherapeuticsNCT00421135Written as ZIO-201
- Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid TumorsCompletedPhase 1Alaunos TherapeuticsNCT00608803Written as ZIO-201-T and doxorubicin
Codes
What other systems call isophosphamide mustard · ClinicalTrials.gg INT002846
- MeSH (NLM) C027061isophosphamide mustardConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6A4U6NN813PALIFOSFAMIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C027061 | isophosphamide mustard | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6A4U6NN813 | PALIFOSFAMIDE | Confirmed FDA, NLM |
Also registered as palifosfamide tromethamine (UNII 0X5A3C04ID).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.